Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mir-10b inhibitor
- Development stage
- Preclinical
- Lead developer
- TransCode Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intratumoral
01
Overview
A miR-10b inhibitor is a type of RNA-targeted therapy designed to silence microRNA-10b (miR-10b), a non-coding RNA that acts as a master regulator of metastatic tumor cell viability and migration. miR-10b is frequently overexpressed in various malignancies, including metastatic breast cancer and glioblastoma multiforme (GBM). These inhibitors typically utilize antisense oligonucleotides (antagomirs), often delivered via nanoparticle systems such as iron oxide or lipid nanoparticles to enhance stability and target delivery to metastatic sites. By inhibiting miR-10b, these agents aim to restore the expression of target genes like HOXD10, thereby suppressing tumor proliferation and metastasis. Key candidates in this class include TTX-MC138, developed by TransCode Therapeutics, and RGLS5579, developed by Regulus Therapeutics.
- Other names
- miR-10b antagomirmiR10b antagomirmiR 10b antagomirmicroRNA-10b inhibitormicroRNA10b inhibitormicroRNA 10b inhibitor
02
Targets
miR-10b (MicroRNA-10b)
Beyond the preview
Go deeper on mir-10b inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mir-10b inhibitor.